Announcement • Jun 30
Amoy Diagnostics Co., Ltd. to Report First Half, 2026 Results on Jul 31, 2026 Amoy Diagnostics Co., Ltd. announced that they will report first half, 2026 results on Jul 31, 2026 Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥17.20, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 24x in the Biotechs industry in China. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥26.39 per share. Board Change • Jun 08
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Qiao Wu was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Apr 30
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.5% to CN¥20.21. The fair value is estimated to be CN¥25.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 6.8%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 13% per annum over the same time period. Reported Earnings • Apr 16
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.90 (up from CN¥0.64 in FY 2024). Revenue: CN¥1.20b (up 8.0% from FY 2024). Net income: CN¥357.9m (up 40% from FY 2024). Profit margin: 30% (up from 23% in FY 2024). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 4.8%. Earnings per share (EPS) also missed analyst estimates by 2.3%. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Apr 16
Amoy Diagnostics Co., Ltd., Annual General Meeting, May 07, 2026 Amoy Diagnostics Co., Ltd., Annual General Meeting, May 07, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China Announcement • Mar 31
Amoy Diagnostics Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Board Change • Mar 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Qiao Wu was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 14
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.90 (up from CN¥0.64 in FY 2024). Revenue: CN¥1.20b (up 8.0% from FY 2024). Net income: CN¥357.9m (up 40% from FY 2024). Profit margin: 30% (up from 23% in FY 2024). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 4.8%. Earnings per share (EPS) also missed analyst estimates by 2.3%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Mar 02
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.2% to CN¥20.21. The fair value is estimated to be CN¥25.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 62% in the next 2 years. Announcement • Dec 31
Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 Announcement • Oct 27
Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares. Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 34.5 per share. The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will used to cancel and reduce the company's registered capital. The authorization will be valid for 12 months. Reported Earnings • Oct 26
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: CN¥0.19 (down from CN¥0.21 in 3Q 2024). Revenue: CN¥286.3m (down 6.1% from 3Q 2024). Net income: CN¥73.5m (down 12% from 3Q 2024). Profit margin: 26% (down from 27% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has remained flat. Announcement • Sep 30
Amoy Diagnostics Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025 Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025 Reported Earnings • Jul 29
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: EPS: CN¥0.25 (up from CN¥0.20 in 2Q 2024). Revenue: CN¥307.3m (flat on 2Q 2024). Net income: CN¥98.6m (up 24% from 2Q 2024). Profit margin: 32% (up from 26% in 2Q 2024). Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 9.0%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Jul 02
Amoy Diagnostics Co., Ltd. to Report First Half, 2025 Results on Jul 29, 2025 Amoy Diagnostics Co., Ltd. announced that they will report first half, 2025 results on Jul 29, 2025 Declared Dividend • May 29
Dividend increased to CN¥0.30 Dividend of CN¥0.30 is 100% higher than last year. Ex-date: 3rd June 2025 Payment date: 3rd June 2025 Dividend yield will be 1.5%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (36% cash payout ratio). The dividend has increased by an average of 29% per year over the past 7 years and payments have been stable during that time. EPS is expected to grow by 69% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Major Estimate Revision • Apr 28
Consensus revenue estimates fall by 16% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥1.54b to CN¥1.29b. EPS estimate fell from CN¥0.966 to CN¥0.83 per share. Net income forecast to grow 25% next year vs 34% growth forecast for Biotechs industry in China. Consensus price target down from CN¥31.13 to CN¥28.82. Share price was steady at CN¥20.72 over the past week. Price Target Changed • Apr 26
Price target decreased by 7.4% to CN¥28.82 Down from CN¥31.13, the current price target is an average from 5 analysts. New target price is 38% above last closing price of CN¥20.89. Stock is down 3.1% over the past year. The company is forecast to post earnings per share of CN¥0.83 for next year compared to CN¥0.64 last year. Board Change • Apr 23
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Zhe Shen was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 23
Amoy Diagnostics Co., Ltd. Proposes Final Cash Dividend for the Year 2024 Amoy Diagnostics Co., Ltd. proposed final cash dividend/10 shares (tax included) of CNY3.00000000 for the year 2024. Reported Earnings • Apr 22
First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2025 results: EPS: CN¥0.23 (up from CN¥0.16 in 1Q 2024). Revenue: CN¥272.1m (up 17% from 1Q 2024). Net income: CN¥90.5m (up 41% from 1Q 2024). Profit margin: 33% (up from 28% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) exceeded analyst estimates by 44%. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Apr 22
Amoy Diagnostics Co., Ltd., Annual General Meeting, May 14, 2025 Amoy Diagnostics Co., Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China Announcement • Mar 31
Amoy Diagnostics Co., Ltd. to Report Q1, 2025 Results on Apr 22, 2025 Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2025 results on Apr 22, 2025 Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥26.34, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 13% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥20.50 per share. Buy Or Sell Opportunity • Feb 17
Now 26% overvalued Over the last 90 days, the stock has fallen 1.0% to CN¥25.70. The fair value is estimated to be CN¥20.47, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has grown by 7.1%. Revenue is forecast to grow by 49% in 2 years. Earnings are forecast to grow by 43% in the next 2 years. Announcement • Dec 31
Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2024 Results on Apr 22, 2025 Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2024 results on Apr 22, 2025 Price Target Changed • Oct 25
Price target increased by 7.0% to CN¥28.92 Up from CN¥27.01, the current price target is an average from 6 analysts. New target price is 12% above last closing price of CN¥25.83. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.80 for next year compared to CN¥0.66 last year. Reported Earnings • Oct 22
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2024 results: EPS: CN¥0.21 (up from CN¥0.12 in 3Q 2023). Revenue: CN¥305.0m (up 23% from 3Q 2023). Net income: CN¥83.4m (up 78% from 3Q 2023). Profit margin: 27% (up from 19% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 6.4%. Earnings per share (EPS) exceeded analyst estimates by 19%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Sep 30
Amoy Diagnostics Co., Ltd. to Report Q3, 2024 Results on Oct 22, 2024 Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2024 results on Oct 22, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to CN¥24.00, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Biotechs industry in China. Total loss to shareholders of 45% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.04 per share. Buy Or Sell Opportunity • Sep 18
Now 20% undervalued The stock has been flat over the last 90 days, currently trading at CN¥18.30. The fair value is estimated to be CN¥22.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has grown by 6.7%. Revenue is forecast to grow by 52% in 2 years. Earnings are forecast to grow by 55% in the next 2 years. Announcement • Aug 16
Amoy Diagnostics Co., Ltd. Elects Shen Zhe and Wu Qiao as Independent Director Amoy Diagnostics Co., Ltd. at the Extraordinary General Meeting of 2024 on 14 August 2024 approved election and nomination of independent directors, cumulative voting system applicable: Shen Zhe, independent director; Wu Qiao, independent director. Buy Or Sell Opportunity • Aug 09
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 13% to CN¥18.42. The fair value is estimated to be CN¥23.04, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.3% over the last 3 years. Earnings per share has grown by 6.7%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 54% in the next 2 years. Reported Earnings • Jul 31
Second quarter 2024 earnings: Revenues and EPS in line with analyst expectations Second quarter 2024 results: EPS: CN¥0.20 (up from CN¥0.18 in 2Q 2023). Revenue: CN¥309.7m (up 18% from 2Q 2023). Net income: CN¥79.7m (up 15% from 2Q 2023). Profit margin: 26% (in line with 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jul 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 18% to CN¥17.51. The fair value is estimated to be CN¥22.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has grown by 8.3%. Revenue is forecast to grow by 51% in 2 years. Earnings are forecast to grow by 52% in the next 2 years. Announcement • Jun 29
Amoy Diagnostics Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024 Amoy Diagnostics Co., Ltd. announced that they will report first half, 2024 results on Jul 30, 2024 Declared Dividend • May 27
Dividend increased to CN¥0.15 Dividend of CN¥0.15 is 7.1% higher than last year. Ex-date: 30th May 2024 Payment date: 30th May 2024 Dividend yield will be 0.8%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased by an average of 20% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • May 25
Amoy Diagnostics Co., Ltd. Announces Cash Dividend on A Shares for the Year 2023, Payable on 30 May 2024 Amoy Diagnostics Co., Ltd. announced final cash dividend of CNY 1.50000000 per ten A shares (tax included) for the year 2023. Record date: 29 May 2024. Ex-date: 30 May 2024. Payment date: 30 May 2024. Reported Earnings • Apr 18
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: CN¥0.66 (down from CN¥0.67 in FY 2022). Revenue: CN¥1.04b (up 24% from FY 2022). Net income: CN¥261.5m (flat on FY 2022). Profit margin: 25% (down from 31% in FY 2022). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.8%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Announcement • Apr 16
Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024 Amoy Diagnostics Co., Ltd., Annual General Meeting, May 13, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China Announcement • Apr 02
Amoy Diagnostics Co., Ltd. (SZSE:300685) commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on February 26, 2024. Amoy Diagnostics Co., Ltd. (SZSE:300685) commences share repurchases on March 29, 2024, under the program mandated by shareholders in the Extraordinary General Meeting held on February 26, 2024. As per the mandate, the company is authorized to repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at no more than CNY 28 per share. The purpose of the program is to cancel the shares and reduce the share capital of the company. The company will use its own fund to fund the repurchase. The authorization will be valid for 12 months. Announcement • Mar 30
Amoy Diagnostics Co., Ltd. to Report Q1, 2024 Results on Apr 23, 2024 Amoy Diagnostics Co., Ltd. announced that they will report Q1, 2024 results on Apr 23, 2024 Price Target Changed • Mar 02
Price target decreased by 7.6% to CN¥29.52 Down from CN¥31.94, the current price target is an average from 7 analysts. New target price is 31% above last closing price of CN¥22.50. Stock is down 24% over the past year. The company is forecast to post earnings per share of CN¥0.62 for next year compared to CN¥0.67 last year. Buy Or Sell Opportunity • Feb 27
Now 24% overvalued Over the last 90 days, the stock has fallen 4.4% to CN¥21.30. The fair value is estimated to be CN¥17.21, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 57% in 2 years. Earnings are forecast to grow by 74% in the next 2 years. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥19.68, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.23 per share. New Risk • Feb 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (22% net profit margin). Announcement • Dec 29
Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024 Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2023 results on Apr 16, 2024 Reported Earnings • Oct 24
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.35 in 3Q 2022). Revenue: CN¥248.9m (up 20% from 3Q 2022). Net income: CN¥47.0m (down 65% from 3Q 2022). Profit margin: 19% (down from 65% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 44%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Amoy Diagnostics Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023 Amoy Diagnostics Co., Ltd. announced that they will report Q3, 2023 results on Oct 24, 2023 Reported Earnings • Aug 01
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Second quarter 2023 results: EPS: CN¥0.18 (up from CN¥0.087 in 2Q 2022). Revenue: CN¥263.5m (up 41% from 2Q 2022). Net income: CN¥69.4m (up 95% from 2Q 2022). Profit margin: 26% (up from 19% in 2Q 2022). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 100%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • Jul 01
Amoy Diagnostics Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023 Amoy Diagnostics Co., Ltd. announced that they will report first half, 2023 results on Aug 01, 2023 Announcement • May 17
Amoy Diagnostics Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023 Amoy Diagnostics Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 1.40000000. Record date: 22 May 2023, Ex-date: 23 May 2023 and Payment date: 23 May 2023. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY0.14000000(10% x CNY1.40000000) Net cash dividend/10 shares after tax: CNY1.26000000(CNY1.40000000- CNY0.14000000). Reported Earnings • Apr 15
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.67 (up from CN¥0.61 in FY 2021). Revenue: CN¥842.2m (down 8.2% from FY 2021). Net income: CN¥263.7m (up 10% from FY 2021). Profit margin: 31% (up from 26% in FY 2021). Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 6.7%. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Price Target Changed • Jan 17
Price target decreased to CN¥35.47 Down from CN¥38.27, the current price target is an average from 5 analysts. New target price is 23% above last closing price of CN¥28.82. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥0.73 for next year compared to CN¥0.61 last year. Board Change • Nov 16
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 3 highly experienced directors. 4 independent directors (5 non-independent directors). Chairman Li-Mou Zheng is the most experienced director on the board, commencing their role in 2008. Non-Independent Director Xin Huang was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Major Estimate Revision • Oct 31
Consensus revenue estimates fall by 18% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥1.09b to CN¥897.6m. EPS estimate fell from CN¥0.78 to CN¥0.74 per share. Net income forecast to grow 17% next year vs 41% growth forecast for Biotechs industry in China. Consensus price target down from CN¥46.45 to CN¥41.29. Share price fell 6.4% to CN¥23.45 over the past week. Price Target Changed • Oct 26
Price target decreased to CN¥41.29 Down from CN¥46.45, the current price target is an average from 5 analysts. New target price is 74% above last closing price of CN¥23.70. Stock is down 46% over the past year. The company is forecast to post earnings per share of CN¥0.76 for next year compared to CN¥0.61 last year. Reported Earnings • Oct 25
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: EPS: CN¥0.35 (up from CN¥0.16 in 3Q 2021). Revenue: CN¥206.8m (down 16% from 3Q 2021). Net income: CN¥134.9m (up 107% from 3Q 2021). Profit margin: 65% (up from 26% in 3Q 2021). Revenue missed analyst estimates by 22%. Earnings per share (EPS) exceeded analyst estimates by 21%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥25.53, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 7.5% over the past three years. Reported Earnings • Jul 31
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Second quarter 2022 results: EPS: CN¥0.087 (down from CN¥0.17 in 2Q 2021). Revenue: CN¥186.5m (down 17% from 2Q 2021). Net income: CN¥35.7m (down 48% from 2Q 2021). Profit margin: 19% (down from 30% in 2Q 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 27%. Earnings per share (EPS) also missed analyst estimates by 49%. Over the next year, revenue is forecast to grow 44%, compared to a 36% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year whereas the company’s share price has increased by 19% per year. Announcement • Jun 07
Amoy Diagnostics Co., Ltd., Annual General Meeting, Jun 20, 2022 Amoy Diagnostics Co., Ltd., Annual General Meeting, Jun 20, 2022, at 14:30 China Standard Time. Agenda: To consider the transfer of the rights and interests of SDC2 product and equities in a subsidiary; and to consider the change of the Company's registered capital and amendments to the Company's articles of association. Announcement • May 27
Amoy Diagnostics Co., Ltd. Announces Dividend, Payable on May 31, 2022 Amoy Diagnostics Co., Ltd. approved 2021 profit distribution plan with cash dividend (tax included) of CNY 2.30000000 per 10 shares. Record date: 30 May 2022, Ex-date: 31May 2022 and Payment date: 31 May 2022. Announcement • May 14
Amoy Diagnostics Co., Ltd. Approves Dividend for 2021 Amoy Diagnostics Co., Ltd. at its Annual General Meeting of 2021 held on 11 May 2022 approved 2021 profit distribution plan with cash dividend (tax included) of CNY 2.30000000 per 10 shares. Price Target Changed • Apr 27
Price target decreased to CN¥82.96 Down from CN¥111, the current price target is an average from 7 analysts. New target price is 90% above last closing price of CN¥43.57. Stock is down 48% over the past year. The company is forecast to post earnings per share of CN¥1.39 for next year compared to CN¥1.09 last year. Board Change • Apr 27
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Deputy GM, Secretary of the Board of Directors & Non-Independent Director Jiemin Luo was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • Apr 13
Price target decreased to CN¥93.33 Down from CN¥111, the current price target is an average from 4 analysts. New target price is 96% above last closing price of CN¥47.51. Stock is down 39% over the past year. The company is forecast to post earnings per share of CN¥1.37 for next year compared to CN¥1.09 last year. Reported Earnings • Apr 12
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥1.09 (up from CN¥0.82 in FY 2020). Revenue: CN¥917.0m (up 26% from FY 2020). Net income: CN¥239.6m (up 33% from FY 2020). Profit margin: 26% (up from 25% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 28%, compared to a 49% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Apr 08
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 32%. The fair value is estimated to be CN¥59.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 71% in 2 years. Earnings is forecast to grow by 83% in the next 2 years. Major Estimate Revision • Mar 17
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥1.24b to CN¥1.12b. EPS estimate also fell from CN¥1.55 per share to CN¥1.32 per share. Net income forecast to grow 26% next year vs 41% growth forecast for Biotechs industry in China. Consensus price target broadly unchanged at CN¥106. Share price was steady at CN¥52.24 over the past week. Reported Earnings • Mar 02
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥1.05 (up from CN¥0.82 in FY 2020). Revenue: CN¥917.0m (up 26% from FY 2020). Net income: CN¥231.4m (up 28% from FY 2020). Profit margin: 25% (in line with FY 2020). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 4.1%. Over the next year, revenue is forecast to grow 36%, compared to a 43% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Announcement • Feb 15
Amoy Diagnostics Co., Ltd. (SZSE:300685) announces an Equity Buyback for CNY 200 million worth of its shares. Amoy Diagnostics Co., Ltd. (SZSE:300685) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its common stock. The shares will be repurchased at a price of CNY 95 per share. The shares repurchased will be used for ESOP or equity incentives. The program will be valid for 12 months. Announcement • Jan 14
Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Limited Announces the Commercial Launch of the AmoyDx® Pan Lung Cancer PCR Panel in Japan Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Limited announced the commercial launch of the AmoyDx®Pan Lung Cancer PCR Panel in Japan as a reimbursed companion diagnostic for multiple anti-cancer agents. AmoyDx is the inventor and manufacturer and PREMIA the developer of the PLC Panel in Japan. Reported Earnings • Oct 27
Third quarter 2021 earnings released: EPS CN¥0.29 (vs CN¥0.21 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥246.8m (up 23% from 3Q 2020). Net income: CN¥65.2m (up 44% from 3Q 2020). Profit margin: 26% (up from 23% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Jul 28
Price target increased to CN¥105 Up from CN¥92.57, the current price target is an average from 6 analysts. New target price is 24% above last closing price of CN¥84.34. Stock is up 6.0% over the past year. Reported Earnings • Jul 26
Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥225.2m (up 17% from 2Q 2020). Net income: CN¥67.9m (up 24% from 2Q 2020). Profit margin: 30% (up from 28% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 30
Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. Announce the Approval of AmoyDx Pan Lung Cancer PCR Panel Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., and Precision Medicine Asia Co., Ltd. announced that the AmoyDx Pan Lung Cancer PCR Panel, an in vitro diagnostic reagent developed as a companion diagnostic for multiple anti-cancer agents, was approved by Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on June 25, 2021. The AmoyDx PLC Panel is based on polymerase chain reaction (PCR) technology, and can simultaneously evaluate the presence of 11 driver genes (EGFR/ALK/ROS1/KRAS/BRAF/HER2/RET/MET/NTRK1/NTRK2/NTRK3 genes) when all genes on the panel are approved as companion diagnostics. The AmoyDx PLC Panel has received approval for four driver genes (EGFR, ALK, ROS1, and BRAF) for nine associated targeted therapies in NSCLC. With its high sensitivity and short turnaround time, The AmoyDx PLC Panel is expected to be an important clinical diagnostic in guiding treatment opportunities for NSCLC patients. Reported Earnings • Apr 14
Full year 2020 earnings released: EPS CN¥0.82 (vs CN¥0.63 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥728.4m (up 26% from FY 2019). Net income: CN¥180.3m (up 34% from FY 2019). Profit margin: 25% (up from 23% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Mar 09
New 90-day low: CN¥67.96 The company is down 8.0% from its price of CN¥74.06 on 09 December 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥19.12 per share. Announcement • Feb 25
Amoy Diagnostics Co., Ltd. to Report Fiscal Year 2020 Results on Apr 13, 2021 Amoy Diagnostics Co., Ltd. announced that they will report fiscal year 2020 results on Apr 13, 2021 Is New 90 Day High Low • Feb 09
New 90-day high: CN¥92.11 The company is up 17% from its price of CN¥78.85 on 11 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥28.03 per share. Is New 90 Day High Low • Jan 22
New 90-day high: CN¥87.26 The company is up 10.0% from its price of CN¥79.00 on 23 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥27.80 per share. 
